STOCK TITAN
  1. Home
  2. News
  3. SLS

SELLAS Life Sciences Group, Inc. - SLS STOCK NEWS

Welcome to our dedicated page for SELLAS Life Sciences Group news (Ticker: SLS), a resource for investors and traders seeking the latest updates and insights on SELLAS Life Sciences Group stock.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company dedicated to the development of novel therapeutics aimed at addressing a broad range of cancer indications. The company's core mission is to practice the medicine of tomorrow, today, by integrating innovative approaches that significantly impact the global healthcare landscape.

SELLAS' leading product candidate is galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms Tumor 1 (WT1) antigen. Licensed from Memorial Sloan Kettering Cancer Center, GPS is designed to treat various hematologic malignancies and solid tumors. Notably, GPS is currently undergoing a Phase 3 REGAL clinical trial for acute myeloid leukemia (AML), with promising safety and efficacy data observed so far.

Another pivotal asset in SELLAS' pipeline is SLS009 (formerly GFH009), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. Licensed from GenFleet Therapeutics (Shanghai), Inc., SLS009 is being explored for its potential to treat relapsed/refractory acute myeloid leukemia (r/r AML) and other cancer types. Recent Phase 2a trial results show that SLS009 exhibits strong anti-leukemic activity, with favorable safety profiles and significant response rates, particularly in patients with identified biomarkers such as the ASXL1 mutation.

SELLAS is committed to advancing these therapeutics through rigorous clinical trials and strategic partnerships. The company collaborates with renowned scientists, healthcare professionals, and pharmaceutical executives to bring cutting-edge treatments to market. Recent collaborations include a clinical trial agreement with BeiGene Switzerland GmbH to study the combination of GFH009 and BRUKINSA® (zanubrutinib) in treating diffuse large B cell lymphoma (DLBCL).

Financially, SELLAS has shown resilience and growth, as evidenced by a successful $20 million registered direct offering in March 2024, bolstering their cash reserves for ongoing R&D activities. The company continues to report sound financial health, marked by a focused approach on strategic developments and clinical milestones.

For more information on SELLAS Life Sciences Group, Inc. and its innovative therapies, visit their official website at www.sellaslifesciences.com.

News

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) has announced a registered direct offering and private placement of common stock and warrants with institutional investors. The Offering includes 13,029,316 shares at $1.535 per share and warrants to purchase the same number of shares at $1.41 per share, expiring in 5.5 years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.03%
Tags
offering
-
News

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) announced a reorganization of its executive leadership to focus on advancing clinical programs efficiently. Key departures include the Chief Commercial Officer and General Counsel. The company aims to enhance shareholder value through asset development, financial stewardship, and strategic partnerships. Anticipated milestones include interim analysis of Phase 3 REGAL trial and topline data releases for various trials. SELLAS is also strengthening its market access strategies and reimbursement initiatives for potential commercial success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
partnership
-
News

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (SLS) announces positive Phase 1 data for SLS009 in AML patients, achieving complete remission with CDK9 inhibition monotherapy. Key objectives met with durable responses and favorable safety profile. Phase 2a data expected in March and Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
clinical trial
News

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. announces a change in the presentation date for data from the acute myeloid leukemia cohort in the Phase 1 study of SLS009 at the 2024 ESH Conference. The presentation will now take place on March 1, 2024, at 12:55 pm CEST in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces a publication in Oncotarget revealing the underlying mechanisms of action behind the anti-proliferative effects of SLS009, its potent CDK9 small molecule inhibitor, in various hematologic malignancies. The research provides a robust pharmacodynamic and mechanistic foundation for the antiproliferative effects of SLS009 in hematologic cancers and shows its potential in tumor growth inhibition with a dose-dependent induction of apoptosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.48%
Tags
clinical trial
-
News

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announces the presentation of data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 at the 2024 ESH Conference. The presentation will be given by Dr. Tapan Kadia, detailing the Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia. The session will take place on Sunday, March 3, 2024, at 12 pm CET in Stockholm, Sweden.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences clinical trial
News

GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia

Rhea-AI Summary
GenFleet Therapeutics (GFH), a clinical-stage biotechnology company, received fast track and orphan drug designations from the FDA for its highly selective CDK9 inhibitor, GFH009, for the treatment of relapsed/refractory peripheral T-cell lymphomas (PTCL) and acute myeloid leukemia (AML). The company is conducting phase II studies for both indications, with positive clinical responses observed in previous studies. GenFleet's partner, Sellas Life Sciences, is also undertaking a phase II trial for GFH009 in combination with other drugs for treating r/r AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
clinical trial
-
News

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Rhea-AI Summary
SELLAS Life Sciences Group, ticker symbol SLS, announced the completion of Phase 2a enrollment for SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia (AML). The Fast Track Designation from the FDA underscores the potential of SLS009, with positive topline Phase 2a data showing significant anti-leukemic effects and an 89% survival rate in the 45 mg dose cohort. The company aims to deliver a potentially groundbreaking treatment to AML patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.64%
Tags
clinical trial
-
News

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced the pricing of a public offering for the purchase and sale of 12,000,000 shares of common stock and accompanying warrants, resulting in total gross proceeds of $9.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
offering
News

SELLAS Life Sciences Announces Proposed Public Offering

Rhea-AI Summary
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced a public offering of shares of its common stock and warrants to purchase shares of common stock. The net proceeds will be used for funding ongoing operations, clinical development of existing product candidates, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.26%
Tags
offering

FAQ

What is the current stock price of SELLAS Life Sciences Group (SLS)?

The current stock price of SELLAS Life Sciences Group (SLS) is $1.22 as of November 21, 2024.

What is the market cap of SELLAS Life Sciences Group (SLS)?

The market cap of SELLAS Life Sciences Group (SLS) is approximately 85.2M.

What does SELLAS Life Sciences Group, Inc. specialize in?

SELLAS Life Sciences Group, Inc. focuses on the development of novel therapeutics for a broad range of cancer indications.

What is GPS in SELLAS' product pipeline?

GPS, or galinpepimut-S, is a peptide immunotherapy targeting the WT1 antigen, designed to treat various cancers and currently in a Phase 3 clinical trial for AML.

What is SLS009?

SLS009 is a highly selective CDK9 inhibitor licensed from GenFleet Therapeutics, being tested for effectiveness in treating relapsed/refractory AML and other cancers.

How is SELLAS contributing to cancer research?

SELLAS advances cancer research through clinical trials of innovative therapies like GPS and SLS009, aiming to address unmet medical needs in oncology.

Who are SELLAS' key partners?

SELLAS collaborates with Memorial Sloan Kettering Cancer Center, GenFleet Therapeutics, and BeiGene Switzerland GmbH for its clinical trials and therapeutic developments.

What financial milestone did SELLAS achieve in 2024?

In March 2024, SELLAS completed a $20 million registered direct offering, enhancing their financial position for ongoing research and development activities.

What recent clinical trial advancements has SELLAS made?

SELLAS recently completed enrollment in the Phase 3 REGAL trial for GPS in AML and reported positive Phase 2a results for SLS009 in r/r AML.

What is the significance of the ASXL1 mutation in SELLAS' research?

The ASXL1 mutation is linked to poor prognosis in myeloid diseases, and SELLAS' SLS009 has shown promising response rates in patients with this mutation, indicating potential for targeted therapy.

Where can I get more information about SELLAS Life Sciences Group, Inc.?

For more details, visit SELLAS Life Sciences Group, Inc.'s official website at www.sellaslifesciences.com.

What is the focus of the collaboration between SELLAS and BeiGene Switzerland GmbH?

The collaboration focuses on a clinical trial combining GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib, BTK inhibitor) to treat diffuse large B cell lymphoma.

Stock SLS logo
SELLAS Life Sciences Group, Inc.

Nasdaq:SLS

SLS Rankings

#4490 Ranked by Market Cap
N/A Ranked by Dividends

SLS Stock Data

85.16M
70.23M
0.24%
7.36%
13.39%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK